Drugs / Lu-177-DOTA-Octreotide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04917484 | Feb 2020 → Dec 2025 overdue | neuroendocrine neoplasm | Tine Gregersen, MD | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lu-177-DOTA-Octreotide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04917484 ↗ |